Quarterly ResultJun 16, 2026, 09:11 AM
Trinity Biotech Q1 Revenue +43% to $10.8M; Gross Margin 35.4%
AI Summary
Trinity Biotech reported Q1 2026 revenues of $10.8 million, a 43% increase year-over-year, with gross margin improving significantly to 35.4% from 25.2%. The company also received additional purchase orders for over 2 million units of its TrinScreen™ HIV rapid test, scheduled for Q3 2026 fulfillment, which are expected to contribute meaningfully to 2026 revenue and profitability. These developments are supported by the ongoing execution of its Comprehensive Transformation Plan, including outsourced manufacturing, which is anticipated to further enhance financial performance.
Key Highlights
- Q1 2026 Revenue increased 43% to $10.8 million from $7.6 million in Q1 2025.
- Gross margin improved to 35.4% in Q1 2026 from 25.2% in Q1 2025.
- Received orders for over 2 million TrinScreen™ HIV rapid tests for Q3 2026 fulfillment.
- Q1 2026 Net Loss reduced to $4.4 million from $8.8 million in Q1 2025.
- Adjusted EBITDA improved to negative $1.1 million from negative $4.0 million in Q1 2025.
- Rapid HIV sales reached $3.7 million in Q1 2026, including $2.3 million from TrinScreen™ HIV.
- Haemoglobin product sales rose to $3.3 million in Q1 2026 from $2.3 million in Q1 2025.
- Company continues commercial scale-up of outsourced UniGold HIV™ production, expected in Q3 2026.
Price Impact
More from TRIB